Responsive Image

 

 

Responsive Image

Oncología clínica

Líneas de investigación

Cáncer de mama (neoadyuvancia, metastásico y adyuvante).
Cáncer de pulmón (localmente avanzado,metastásico).
Oncogeriatría.
Trombosis en cáncer.
Cáncer genitourinario.
Cáncer de cabeza y cuello.

Coordinador/a del grupo



Miembros del grupo

  María Teresa Abad Villar
 
 
  María Purificación Martínez Del Prado
 
 
  María Ángeles Sala González
 
 
  Laura Sande Sardina
 
 
  Maitane Nuño Escolástico
 
 
  Patricia Novas Vidal
 
 
  Borja López De San Vicente Hernández
 
 
  María López Santillán
 
 
  Ane Zumarraga Cuesta
 
 
  Jairo Legaspi Folgueira
 
 
  María Pérez Hoyos
 
 

Publicaciones del grupo

Casas A, Ciruelos E, Oliveira M, Saura C, Bellet M, Pernas S, et al. Solti-1903 HOPE: Real-world clinical practice study to assess the impact of using genomic data on the next treatment decision making-choice in patients with locally advanced or metastatic breast cancer in Spain. Cancer Res. 2022; 82(4). DOI:10.1158/1538-7445.SABCS21-OT2-06-01.

Silva Cardenas DC, Pikabea Diaz F, Zumarraga Cuesta A, Lopez Santillan M, Figaredo Berjano C, Loaiza Jaramillo PL, et al. Real-world data: incidence of venous thromboembolism recurrence and bleeding among cancer patients. Thromb Res. 2022; 213: 17-17

Diaz FP, Calvo EG, Zumarraga A, Bejarano CF, Gonzalez M, Santillan ML, et al. Predicting Oncotype DX recurrence scores using clinicopathologic features: Tennessee University Nomogram: An external validation. Ann Oncol. 2022; 33: 233-233. DOI:10.1016/j.annonc.2022.03.258.

Dafni U, Soo RA, Peters S, Tsourti Z, Vervita K, Han JY, et al. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis. Ann Oncol. 2022; 33: 46-47. DOI:10.1016/j.annonc.2022.02.041.

de Juan VC, Dols MC, Rodriguez Abreu D, Carcereny E, Cantero A, Caro RB, et al. Determination of essential biomarkers in lung cancer: A real-world data study in Spain. Ann Oncol. 2022; 33: 50-50. DOI:10.1016/j.annonc.2022.02.048.

Casas A, Ciruelos E, Oliveira M, Saura C, Bellet M, Pernas S et al. Solti-1903 hope: Real-world clinical practice study to assess the impact of using comprehensive genomic data on the next treatment decision making-choice in patients with locally advanced or metastatic breast cancer in Spain. Cancer Res. 2021; 81(4).

Provencio M, Mazarico Gallego JM, Calles A, Antoñanzas M, Pangua C, Mielgo Rubio X et al. Lung cancer patients with COVID-19 in Spain: GRAVID study. Lung Cancer. 2021; 157: 109-115. DOI:10.1016/j.lungcan.2021.05.014.

Provencio M, Majem M, Guirado M, Massuti B, de Las Penas R, Laura Ortega A et al. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. Lung Cancer. 2021; 153: 25-34. DOI:10.1016/j.lungcan.2021.01.005.

Lopez Santillan M, Lopez E, Alvarez Gonzalez P, Martinez G, Arzuaga Mendez J, Ruiz Diaz I et al. Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review. Crit Rev Oncol Hematol. 2021; 165: 103430-103430. DOI:10.1016/j.critrevonc.2021.103430.

Garcia R,Arrieta O,Massuti B,Rodriguez D,Ortega AL,Majem M,Vicente D,Lianes P,Bosch J,Insa A,Domine M,Reguart N,Guirado M,Angeles M,Vazquez S,Bernabe R,Drozdowskyj A,Verdu A,Karachaliou N,Molina MA,Rosell R,SLCG. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Lung Cancer. 2020. 150. p. 62-69. IF:5,705. (1).  

Subbiah V,Paz L,Besse B,Moreno V,Peters S,Angeles M,Antonio Lopez J,Fernandez C,Kahatt C,Alfaro V,Siguero M,Zeaiter A,Zaman K,Lopez R,Ponce S,Boni V,Arrondeau J,Delord J,Martinez M,Wannesson L,Anton A,Valdivia J,Awada A,Kristeleit R,Eugenia M,Jesus M,Sarantopoulos J,Chawla SP,Mosquera J,D'Arcangelo M,Santoro A,Villalobos VM,Sands J,Trigo J. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer. 2020. 150. p. 90-96. IF:5,705. (1).  

Barquin M,Calvo V,Garcia F,Nunez B,Sanchez E,Serna R,Auglyt M,Carcereny E,Rodriguez D,Castro RL,Guirado M,Camps C,Bosch J,Massuti B,Ortega AL,del Barco E,Gonzalez JL,Aguiar D,Garcia R,Domine M,Agraso S,Sala MA,Oramas J,Bernabe R,Blanco R,Parejo C,Cruz A,Menasalvas E,Royuela A,Romero A,Provencio M. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation. Cancer Epidemiol. 2020. 67. 101737. IF:2,984. (2).  

Trigo J,Subbiah V,Besse B,Moreno V,López R,Sala MA,Peters S,Ponce S,Fernández C,Alfaro V,Gómez J,Kahatt C,Zeaiter A,Zaman K,Boni V,Arrondeau J,Martínez M,Delord JP,Awada A,Kristeleit R,Olmedo ME,Wannesson L,Valdivia J,Rubio MJ,Anton A,Sarantopoulos J,Chawla SP,Mosquera J,D'Arcangelo M,Santoro A,Villalobos VM,Sands J,Paz L. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020. 21. (5):p. 645-654. IF:41,316. (1).  

Bermejo de Las Heras B,Cortes Ramon Cajal YJ,Galve E,de la Haba J,Garcia J,Moreno F,Pelaez I,Rodriguez A,Rodriguez CA,Ruiz M,Remak E,Barra M,Rivero M,Soto J. The economic burden of metastatic breast cancer in Spain. Eur. J. Hosp. Pharm.-Sci. Pract. 2020. 27. (1):p. 19-24. IF:1,652. (4).  

Remon J,Nadal E,Domine M,Ruffinelli J,Garcia Y,Pardo JC,Lopez R,Cilleruelo A,Garcia R,Martin P,Juan O,Gonzalez JL,Provencio M,Olmedo E,Ponce S,Cumplido D,Barenys C,Majem M,Massutti B,Rodriguez D,Porta R,Sala MA,Martinez M,Lianes P,Reguart N. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. Lung Cancer. 2020. 147. p. 83-90. IF:5,705. (1).  

Manso L,Hernando C,Galan M,Oliveira M,Cabrera MA,Bratos R,Rodriguez CA,Ruiz M,Blanch S,Llombart A,Delgado JI,Alvarez I,Gallegos I,Gonzalez L,Morales S,Aguirre E,Hernando BA,Ballesteros A,Ales JE,Reboredo C,Oltra A,Gonzalez M,Santisteban M,Malon D,Echeverria I,Garcia E,Vega E,Servitja S,Andres R,Robles CE,Lopez R,Galve E,Echarri MJ,Legeren M,Moreno F. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP). Breast. 2020. 54. p. 286-292. IF:4,380. (1).

© 2022 IIS Biocruces Bizkaia